Doubling the dose of Tadagra 20 mg, or any medication containing tadalafil, can potentially increase the risk of side effects, including those affecting vision and hearing. Tadalafil, the active ingredient in Tadagra, is a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED) and symptoms of benign prostatic hyperplasia (BPH). Here are some potential effects on vision or hearing associated with doubling the dose of Tadagra 20 mg:

1. 
   

   Vision Changes: Tadalafil has been associated with rare but serious ocular side effects, including non-arteritic anterior ischemic optic neuropathy (NAION), a condition characterized by sudden vision loss or changes in vision. Doubling the dose of Tadagra 20 may increase the risk of these ocular side effects. Additionally, some individuals may experience transient vision changes, such as blurred vision or changes in color vision, as a common side effect of tadalafil.

   
   


2. 
   

   Hearing Loss: In rare cases, tadalafil has been associated with sudden hearing loss or changes in hearing. Doubling the dose of Tadagra may increase the risk of these auditory side effects. It's essential to seek medical attention promptly if you experience sudden hearing loss or changes in hearing while taking tadalafil.

   
   

It's important to note that the occurrence of these side effects is rare, but they can potentially occur with any dose of tadalafil, including doubling the dose of Tadagra 20 mg. If you experience any vision changes, hearing loss, or other adverse effects while taking Tadagra, contact your healthcare provider for further evaluation and guidance.

It's crucial to follow the prescribed dosage and instructions provided by your healthcare provider to minimize the risk of side effects and ensure safe and effective treatment. Do not double the dose of Tadagra or any medication without consulting with your doctor first. Your healthcare provider can provide personalized recommendations based on your individual health status and medical history.